Dyslipidemias, Hypertension
Conditions
Brief summary
A phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348(6).
Interventions
DRUGCKD-348(6)
QD, PO
QD, PO
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult volunteers aged ≥ 19 years. 2. Body weight ≥55kg with calculated body mass index (BMI) of 18 to 30 kg/m2 3. Those who meet the blood pressure criteria during screening tests: * Systolic Blood Pressure: 90 to 139 mmHg * Diastolic Blood Pressure: 60 to 89 mmHg 4. Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings. 5. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and ECG results at screening. 6. Those who agree to contraception during the participation of clinical trial. 7. Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.
Exclusion criteria
1. Those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs. 2. Those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month and those who take drug could affect to clinical trial within 10 days before the first administration of investigational products. 3. Those who donated whole blood or apheresis within 8 weeks or 4 weeks respectfully, or received blood transfusion within a month. 4. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery. 5. Those who exceed an alcohol and cigarette consumption criteria write below within 1 month before the first administration of investigational products. * Alcohol: Man - 21 glasses/week, Woman - 14 glasses/week (1glass: Soju 50mL, Wine 30mL, or beer 250mL) * Smoking: 20 cigarettes/day 6. Those who have any history of diabetic mellitus, nephropathy, biliary obstruction, shock, angioedema, cardiac insufficiency, dihydropyridine sensitivity, unstable angina, hypothyroidism and hypersensitive to Sunset yellow FCF. 7. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption. 8. Those who are deemed insufficient to participate in this clinical trial by investigators. 9. Woman who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCt of CKD-348(6) | Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours | AUCt: Area under the concentration-time curve from time zero to time |
| Cmax of CKD-348(6) | Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours | Cmax: Maximum plasma concentration of the drug |
Countries
South Korea
Outcome results
None listed